Antibody-Drug Conjugates: The Hottest Modality in M&A

Introduction

Antibody-drug conjugates have emerged as the single hottest modality in biotech M&A, driving the largest transactions and the highest acquisition premiums in the sector. The combination of proven clinical efficacy, a growing market, platform technology barriers, and the patent cliff imperative for oncology pipeline replenishment has made ADC companies the most sought-after acquisition targets in healthcare. Understanding ADC science, economics, and deal dynamics is increasingly important for healthcare bankers because the modality has driven more M&A dollar volume in recent years than any other single therapeutic class.

An ADC consists of three components, each of which contributes distinct value to the overall molecule and to the company's technology platform:

Antibody. A monoclonal antibody that targets a specific protein (antigen) expressed on cancer cells. The antibody acts as a guided delivery vehicle, carrying the toxic payload directly to the tumor while sparing healthy tissue. The choice of target antigen determines which cancers the ADC can treat. HER2-targeting ADCs (like Enhertu) treat breast and gastric cancers; Nectin-4-targeting ADCs (like Padcev) treat bladder cancer. Antibody engineering, including modifications to improve internalization (the process by which the cancer cell absorbs the ADC), is a significant area of innovation.

Linker. A chemical connection between the antibody and the payload. The linker must be stable enough to survive circulation in the bloodstream (preventing premature release that would cause systemic toxicity, essentially untargeted chemotherapy) but must cleave reliably once the ADC is internalized into the cancer cell. Linker technology is one of the most important differentiators between ADC platforms. Cleavable linkers release the payload inside the cell through enzymatic or pH-dependent mechanisms; non-cleavable linkers require the entire antibody to be degraded before the payload is released. Each approach has different efficacy and safety profiles.

Payload. A potent cytotoxic agent (chemotherapy drug) that kills the cancer cell from within. Payloads used in ADCs are typically 100-1,000x more toxic than standard chemotherapy drugs, which is precisely why they must be delivered via targeted antibody rather than administered systemically. The two dominant payload classes are auristatins (used in Adcetris and Padcev) and camptothecin derivatives (used in Enhertu and Trodelvy). Next-generation payloads, including immune-stimulating agents (replacing cytotoxic payloads with molecules that activate the immune system), represent an emerging innovation frontier.

Drug-to-Antibody Ratio (DAR)

The average number of cytotoxic payload molecules attached to each antibody molecule. Higher DARs deliver more payload per antibody but can affect the ADC's pharmacokinetic properties and tolerability. DAR optimization is a key part of ADC engineering and represents part of the technology platform value that commands premium valuations. First-generation ADCs typically had DARs of 3-4; next-generation ADCs explore DARs of 8+ using novel linker chemistry that maintains stability at higher loading. Daiichi Sankyo's proprietary linker-payload technology (the DXd platform used in Enhertu) achieves a DAR of approximately 8, which is a key reason for Enhertu's superior efficacy and clinical differentiation.

The ADC market has grown rapidly, with over 15 approved products generating approximately $15.6 billion in revenue in 2024. Market projections range from $25 billion to $57 billion by 2035, driven by expanding indications (each approved ADC is being tested in additional cancer types), new targets (moving beyond established antigens to novel tumor targets), and next-generation technology improvements in all three components.

Enhertu's dominance illustrates how a single ADC with superior technology can become a blockbuster franchise. Its revenue trajectory (from launch to over $6 billion in approximately four years) reflects both the clinical differentiation of the DXd platform and the commercial execution of the Daiichi Sankyo/AstraZeneca partnership.

Bystander Effect

A phenomenon where the cytotoxic payload released inside one cancer cell diffuses to kill neighboring cancer cells, even if those neighboring cells do not express the target antigen. ADCs with cleavable linkers and membrane-permeable payloads exhibit a stronger bystander effect, which is clinically advantageous in tumors with heterogeneous antigen expression (where not every cancer cell displays the target protein). The bystander effect is one reason why Enhertu (which has a cleavable linker and a membrane-permeable payload) has shown efficacy even in tumors with low HER2 expression, a finding that dramatically expanded its addressable market.

ADCs have driven the three largest biotech M&A transactions of the past five years, with combined deal value exceeding $74 billion:

The premiums paid in these transactions (33-108%) reflect the competitive intensity among Big Pharma bidders seeking ADC platforms to fill oncology pipeline gaps. In several cases, multiple pharma companies bid for the same ADC target, creating auction dynamics that drove valuations well above standalone rNPV analysis.

The ADC field is evolving rapidly, with several innovation vectors that will drive future deal activity:

The next article covers cell and gene therapy, another transformative modality with distinct economic challenges.